文献速递免疫规划卫生政策与健康促进

评估改良流感疫苗的更广泛影响:疫苗全价值评估方法

Evaluating the broader impact of improved influenza vaccines: A full value of vaccine assessment approach.
PubMed 文献 · Vaccine · 2026-02-17

为量化下一代改良流感疫苗的价值并识别其上市后可能限制接种的挑战,研究采用混合方法(快速文献评估、利益相关者访谈与调查、定量数据分析)开展疫苗全价值评估。在最低假定价格点下,引入改良流感疫苗可在9–48%的国家具有成本效果,但价格和未来疫苗覆盖率的不确定性可能影响潜在成本效果。

要点

  • 最低假定价格点下,改良流感疫苗可在9–48%的国家具有成本效果。
  • 价格与未来覆盖率的不确定性可能影响成本效果,强分层定价可提升更多国家的成本效果。

核心结论

  • 广泛使用改良流感疫苗可在现行疫苗基础上额外大幅减少流感疾病负担,并可能在部分国家具有成本效果。

研究设计与样本

  • 采用混合方法,包括快速文献评估、利益相关者访谈与调查以及定量数据分析,以估算改良流感疫苗的全价值。

主要发现

  • 在最低假定价格点下,引入改良流感疫苗可在9–48%的国家具有成本效果。
  • 价格和未来疫苗覆盖率的不确定性可能影响潜在成本效果。
  • 从生产者角度看,在成熟和新兴市场开发并商业化改良流感疫苗均具有稳健的财务价值主张。
  • 强分层定价可使改良流感疫苗在更多国家具有成本效果并进一步增强影响。

临床怎么用

  • 疫苗开发者、制造商、捐助方、融资方、多边组织及政策与决策者需有效协作,以确保改良流感疫苗实现最大公共卫生效益。

局限性

  • 价格和未来疫苗覆盖率的不确定性可能影响成本效果的估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Seasonal influenza remains a significant global public health challenge, causing substantial morbidity and mortality each year and there remains a need for more effective and durable influenza vaccines. To direct and accelerate research efforts, a full value of vaccine assessment (FVVA) was initiated to quantify the value of next-generation, improved influenza vaccines and identify key challenges that may limit their uptake once available. The FVVA utilized a mixed-methods approach with rapid assessment of literature, stakeholder interviews, and surveys, and quantitative data analysis to estimate the full value of influenza vaccines with improved characteristics. These analyses found that if improved influenza vaccines are broadly employed, depending on their characteristics, using our demand forecast they could avert 6.6-18 billion additional influenza cases, 2.3-6.2 million additional influenza deaths, and 21-57 million disability-adjusted life years (DALYs) between 2025 and 2050 beyond those averted by current seasonal influenza vaccines. Under this scenario, introducing improved influenza vaccines could be cost-effective in 9-48 % of countries at the lowest assumed price point. However, uncertainties about price and future vaccine coverage may impact the potential cost-effectiveness. Furthermore, from the producer perspective, the FVVA highlighted the robust financial value proposition to develop and commercialize improved influenza vaccines, in both established and emerging markets. Strongly tiered prices could make these vaccines cost-effective in more countries and boost impact further. To ensure that improved influenza vaccines achieve the greatest public health benefit, effective collaboration between vaccine developers, vaccine manufacturers, donors, financiers, multilateral organisations, and policy- and decision-makers will be essential.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Soble A, Koh M, Taaffe J, et al. Evaluating the broader impact of improved influenza vaccines: A full value of vaccine assessment approach. Vaccine. 2026. PMID: 41707570. doi:10.1016/j.vaccine.2025.128166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。